This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n14http://www.drugs.com/ppa/
n19http://www.rxlist.com/
n17http://linked.opendata.cz/resource/drugbank/drug/DB08874/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB08874/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB08874/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB08874/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB08874/identifier/wikipedia/
n7http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08874
rdf:type
n3:Drug
n3:description
One of the first narrow spectrum macrocyclic antibiotic, it is a natural compound and is structurally similar to compounds in lipiarmycin-a fermentation mixture. FDA approved on May 27, 2011.
n3:dosage
n10:271B59DF-363D-11E5-9242-09173F13E4C5 n10:271B59E0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Artsimovitch I, Seddon J, Sears P: Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis. 2012 Aug;55 Suppl 2:S127-31. doi: 10.1093/cid/cis358. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22752861 # Crawford T, Huesgen E, Danziger L: Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22610025
n3:group
approved
n3:halfLife
200 mg, healthy subjects = 11.7 hours
n3:indication
Treatment of Clostridium difficile-associated diarrhea
owl:sameAs
n12:DB08874
dcterms:title
Fidaxomicin
adms:identifier
n16:Fidaxomicin n17:D09394 n18:52015-080-01 n20:68590 n21:DB08874
n3:mechanismOfAction
Fidaxomicin is a bactericidal-type antibiotic that inhibits RNA polymerase sigma subunit. RNA polymerase is responsible for transcription in the bacteria therefore fidaxomicin will inhibit protein synthesis. As a result, apoptosis is triggered in susceptible organisms such as C. difficile.
n3:patent
n9:7906489 n9:7378508 n9:7863249
n3:routeOfElimination
Feces (>92% as unchanged drugs and metabolites) and urine (<1% of drug was excreted)
n3:synonym
Tiacumicin B Lipiarrmycin Dificid PAR 101 Difimicin Lipiarmicin PAR-101 OPT 80 Lipiarmycin OPT-80
n3:volumeOfDistribution
Fidaxomicin is largely confined in the gastrointestinal tract and is not distributed extensively in the systemic.
n5:hasAHFSCode
n6:8-12-12-92
n3:foodInteraction
Food decreases Cmax of fidaxomicin and its metabolites however this is not considered clinically significant.
n3:synthesisReference
Youe-Kong Shue, Chi-Jen Frank Du, Ming-Hsi Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin W. Okumu, Jonathan James Duffield, "Medium for the Production of Tiacumicin B." U.S. Patent US20100028970, issued February 04, 2010.
foaf:page
n14:fidaxomicin.html n19:dificid-drug.htm
n3:IUPAC-Name
n4:271B59E5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B59EB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B59EA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B59E7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B59E8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B59E9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B59E3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B59E4-363D-11E5-9242-09173F13E4C5 n4:271B59E1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B59E2-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n7:A07AA12
n3:H-Bond-Acceptor-Count
n4:271B59F1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B59F2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B59EC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B59ED-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B59EF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B59EE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B59F0-363D-11E5-9242-09173F13E4C5
n3:absorption
Fidaxomicin is not systemically absorbed as shown by a plasma concentrations below the lower limit of quantification after single-dose or multiple-dose. In contrast, fecal concentrations of fidaxomicin are much higher and are concentration-dependent. Cmax = 2 hours; Tmax = 5.2 ng/mL; AUC = 14 ng•hr/mL
n3:affectedOrganism
Peptoclostridium difficile Gram-positive Bacteria
n3:casRegistryNumber
873857-62-6
n3:category
n3:Bioavailability
n4:271B59F7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B59F9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B59FA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B59F6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B59F5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B59F8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B59E6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B59F3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B59F4-363D-11E5-9242-09173F13E4C5